View ValuationMirion Technologies 将来の成長Future 基準チェック /46Mirion Technologies利益と収益がそれぞれ年間49.5%と10.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.6% 57.4%なると予測されています。主要情報49.5%収益成長率57.39%EPS成長率Electronic 収益成長39.2%収益成長率10.4%将来の株主資本利益率9.57%アナリストカバレッジGood最終更新日05 May 2026今後の成長に関する最新情報お知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.お知らせ • Apr 30Mirion Technologies, Inc. Revises Earnings Guidance for the Full Year 2025Mirion Technologies, Inc. revised earnings guidance for the full year 2025. Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08. Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024.お知らせ • Feb 13Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points. Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024.お知らせ • Dec 04Mirion Technologies, Inc. Provides Earnings Guidance for the Year 2025Mirion Technologies, Inc. provided earnings guidance for the year 2025. For the year, the company expects Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024. Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points.すべての更新を表示Recent updatesお知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.お知らせ • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026お知らせ • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.お知らせ • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.お知らせ • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026お知らせ • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.お知らせ • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025お知らせ • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35お知らせ • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6お知らせ • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.お知らせ • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.お知らせ • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025お知らせ • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value Indexお知らせ • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.お知らせ • Apr 30Mirion Technologies, Inc. Revises Earnings Guidance for the Full Year 2025Mirion Technologies, Inc. revised earnings guidance for the full year 2025. Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08. Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024.お知らせ • Apr 21Mirion Technologies, Inc. to Report Q1, 2025 Results on Apr 29, 2025Mirion Technologies, Inc. announced that they will report Q1, 2025 results After-Market on Apr 29, 2025お知らせ • Apr 03Mirion Technologies, Inc., Annual General Meeting, May 15, 2025Mirion Technologies, Inc., Annual General Meeting, May 15, 2025.お知らせ • Apr 02Mirion Technologies, Inc. to Elevate Radiopharmaceutical Production Quality with Advanced Apex-Guard SoftwareMirion Technologies announced the latest release of its Apex-Guard gamma spectroscopy software. Tailored to meet the stringent regulatory demands of commercial radioisotope producers, Apex-Guard software V1.2 significantly enhances the Mirion solutions suite within the radiopharmaceutical supply chain with a robust impurity analysis for radioisotope producers. This software release reinforces the Mirion commitment to improving quality in cancer care, through focused innovation across its Mirion Technologies and Mirion Medical groups. The radiopharmaceutical field is experiencing rapid expansion, with over 100 drugs currently in Phase I or further clinical development stages poised to revolutionize patient-centric diagnosis and treatment in cancer care and other medical specialties. To manage the growth, radioisotope producers require robust quality management and impurity analysis to ensure compliance and patient safety. Building on the established Mirion Technologies Genie and Apex-Gamma gamma spectroscopy software platforms, Apex-Guard software offers advanced controls, security, audit features, and data integrity. These features support compliance with regulations such as U.S. FDA 21 CFR Part 112. The latest version introduces a solution for Radionuclidic purity gamma spectroscopy measurements through a broadly applicable, ready-to-use patent-pending algorithm. This advancement streamlines quality management processes, increases confidence in quality and facilitates efficient regulatory compliance. Apex-Guard software further enhances the radiopharmaceutical lifecycle through streamlined workflows via interoperability with industry-leader BioTrax QMS, an electronic quality management tool encompassing inventory management, document management, and production batch records from ec2 Software, a Mirion Medical Company.お知らせ • Mar 01Mirion Technologies Site in Munich Achieves ISO 19443 CertificationMirion Technologies announced that its site in Munich, Germany, has been awarded with the International Organization for Standardization (ISO) certification ISO 19343:2018, a nuclear-specific quality management standard dedicated to organizations supplying products and services important to nuclear safety (ITNS). Such achievement emphasizes the company's commitment to maintaining stringent quality and safety standards specific to the nuclear sector. The Mirion Technologies site in Munich, a full-service provider for Radiation and Neutron Flux Monitoring Systems, is one of a few companies in Germany to receive this certification, building on its long-standing ISO 9001 certification and further enhancing the Mirion commitment to excellence. The audit was conducted by TUV Sud France, accredited by the French Accreditation Body COFRAC. The certification audit specifically highlighted the company's clear line of responsibility, quality concept and emphasis on nuclear quality goals. The auditors also praised the interaction between departments and the well-structured approach to projects and developments. The Munich site joins three other Mirion locations to achieve the ISO 19343 certification. Mirion Technologies sites in France (Lamanon and Fussy) are also accredited.お知らせ • Feb 13Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points. Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024.お知らせ • Jan 17Mirion Technologies, Inc. to Report Q4, 2024 Results on Feb 11, 2025Mirion Technologies, Inc. announced that they will report Q4, 2024 results After-Market on Feb 11, 2025お知らせ • Dec 04Mirion Technologies, Inc. Provides Earnings Guidance for the Year 2025Mirion Technologies, Inc. provided earnings guidance for the year 2025. For the year, the company expects Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024. Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points.お知らせ • Dec 03Mirion Technologies, Inc. (NYSE:MIR) announces an Equity Buyback for $100 million worth of its shares.Mirion Technologies, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its Class A common stock.Reported Earnings • Oct 30Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.061 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (further deteriorated from US$0.061 loss in 3Q 2023). Revenue: US$206.8m (up 8.2% from 3Q 2023). Net loss: US$13.6m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 30Mirion Technologies, Inc. Revises Financial Guidance for the Fiscal Year Ending December 31, 2024Mirion Technologies, Inc. revised financial guidance for the fiscal year ending December 31, 2024. For the period, the company expects revenue growth of 6% to 7%, compared to 5% to 7% previously and Organic revenue growth of 5% to 6%, compared to 4% to 6% previously.New Risk • Oct 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$31m net loss next year). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€250k sold).お知らせ • Oct 17Mirion Technologies, Inc. to Report Q3, 2024 Results on Oct 29, 2024Mirion Technologies, Inc. announced that they will report Q3, 2024 results After-Market on Oct 29, 2024New Risk • Aug 09New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €328k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€328k sold).お知らせ • Aug 03Mirion Technologies, Inc. Reiterates Revenue Guidance for the Full Year Period Ending December 31, 2024Mirion Technologies, Inc. reiterated revenue guidance for the full year period ending December 31, 2024. For the year, the company expects revenue growth guidance of 5% to 7%. Organic revenue growth of 4% - 6%, which is unchanged.Reported Earnings • Aug 02Second quarter 2024 earnings released: US$0.058 loss per share (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: US$0.058 loss per share (improved from US$0.14 loss in 2Q 2023). Revenue: US$207.1m (up 5.0% from 2Q 2023). Net loss: US$11.7m (loss narrowed 58% from 2Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Share price has been volatile over the past 3 months (6.6% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).お知らせ • Jul 20Mirion Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024Mirion Technologies, Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024New Risk • Jul 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).New Risk • Jun 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (2.7% increase in shares outstanding).Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.8m in 2025.Reported Earnings • May 01First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (improved from US$0.22 loss in 1Q 2023). Revenue: US$192.6m (up 5.8% from 1Q 2023). Net loss: US$25.8m (loss narrowed 38% from 1Q 2023). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.お知らせ • May 01Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024Mirion Technologies, Inc. reaffirmed earnings Guidance for the year ending December 31, 2024. The company expected revenue growth of 5% - 7%. Organic revenue growth of 4% - 6%.Board Change • Apr 25High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 24Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider Elect directors for a one-year term; to Ratify the appointment of Deloitte & Touche, LLP (“Deloitte”) as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to Approve, on a non-binding advisory basis, the compensation of company's named executive officers as disclosed in the accompanying proxy statement (the “Say-on-Pay Proposal”); and to transact any other business as may properly come before the meeting or any adjournment, postponement or continuation thereof.New Risk • Apr 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$13m net loss in 2 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).お知らせ • Apr 19Mirion Technologies, Inc. to Report Q1, 2024 Results on Apr 30, 2024Mirion Technologies, Inc. announced that they will report Q1, 2024 results After-Market on Apr 30, 2024Reported Earnings • Mar 04Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022)Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany.Breakeven Date Change • Feb 15No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.5m in 2025.Reported Earnings • Feb 14Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022)Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany.お知らせ • Feb 14Mirion Technologies, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2024Mirion Technologies, Inc. provided earnings guidance for the fiscal year ending December 31, 2024. For the year, the company expects revenue growth of 5% - 7%, and Organic revenue growth of 4% - 6%.お知らせ • Feb 01Mirion Technologies, Inc. to Report Q4, 2023 Results on Feb 13, 2024Mirion Technologies, Inc. announced that they will report Q4, 2023 results After-Market on Feb 13, 2024お知らせ • Nov 03Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million.Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million on November 1, 2023. The ec 2 team and portfolio of solutions will be integrated into Mirion’s Nuclear Medicine business unit.Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Nuclear Medicine Information Systems, LLC on November 1, 2023.Reported Earnings • Nov 02Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.26 loss in 3Q 2022)Third quarter 2023 results: US$0.061 loss per share (improved from US$0.26 loss in 3Q 2022). Revenue: US$191.2m (up 19% from 3Q 2022). Net loss: US$12.1m (loss narrowed 74% from 3Q 2022). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.お知らせ • Nov 02Mirion Technologies, Inc. Reiterates Revenue Guidance for the Twelve Month Period Ending December 31, 2023Mirion Technologies, Inc. reiterates revenue guidance for the twelve month period ending December 31, 2023. The company expects Revenue growth of 8% - 10% and Organic revenue growth of 6% - 8%.お知らせ • Oct 19Mirion Announces Resignation of Michael Rossi as Medical Group President, Effective November 1, 2023Mirion announced that Michael Rossi has informed the Company of his decision to resign as Medical Group President, effective November 1, 2023, in order to assume a CEO role at another public company. Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named. Mr. Logan had previously served as acting Medical Group President through much of 2022.お知らせ • Oct 18Mirion Technologies, Inc. to Report Q3, 2023 Results on Nov 01, 2023Mirion Technologies, Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023New Risk • Aug 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$270m Forecast net loss in 1 year: US$59m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$59m net loss next year). Shareholders have been diluted in the past year (9.3% increase in shares outstanding).Breakeven Date Change • Aug 03No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$60.9m in 2023. New consensus forecast suggests the company will make a loss of US$32.3m in 2024.お知らせ • Aug 03Mirion Technologies, Inc. Updates Its Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. updated its revenue guidance for the fiscal year ending December 31, 2023. For the period, the company expects revenue growth of8% - 10%, compared to 6% - 9% previously and Organic revenue growth of 6% - 8%, compared to 4% - 7% previously.New Risk • Jul 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.お知らせ • Jul 23Mirion Technologies, Inc. to Report Q2, 2023 Results on Aug 02, 2023Mirion Technologies, Inc. announced that they will report Q2, 2023 results on Aug 02, 2023お知らせ • Jun 28Mirion Technologies Introduces Genie™? 4.0 Spectroscopy Software, Now with Flexible Licensing OptionsMirion Technologies announced a major update of the company's Genie spectroscopy software. With the release of Genie 4.0 software, Mirion builds upon nearly 40 years of leadership in spectroscopy solutions and services, delivering a range of new features that enhance efficiency and accuracy for both existing and new users, while introducing simplified software models and flexible purchasing options. Smart Design for All Longtime Genie software users will appreciate the seamless transition to Genie 4.0, as the update retains vital workflows and addresses key user requests, allowing them to maintain productivity and strengthen their expertise. Simultaneously, new users can quickly adapt to and harness the power of the Genie 4.0 release, ensuring evolved spectroscopy operations from the outset. Highlights of Genie 4.0 software include: User Experience Enhancements: Genie 4.0 features new Interactive Reports, enabling easier data visualization and detailed analysis, as well as customization per user requirements. Increased Accuracy and Reliable Results: New algorithms within Genie 4.0 improve uncertainty calculations for relationships in calibration standards and address a frequent user request for a new FWHM calibration curve, to further enhance accuracy. Improved Automation: New Python programming language-based scripting options enable custom and automated modulation of parameters, as well as extraction of specific parameters for analysis in a secondary system. Genie 4.0 software with Python compatibility also empowers users to perform custom calculations and update the analysis as needed, providing added flexibility and adaptability. Interested customers across the fields of Nuclear Power, Emergency Response, Environmental Labs, National Labs, Research, and Education are encouraged to view a free, introductory webinar, Latest in Gamma Spectroscopy: NewGenie 4.0 Software, on mirion.com. Continuous Support and Updates: In addition to a host of new features, the release of Genie 4.0 software introduces flexible new licensing models. Users now have the option to subscribe to the software over one-year or three-year terms with Priority Technical Support and software updates included, thereby lowering total cost of ownership and supporting Operational Expense (OpEx) budgeting. Users may also choose a non-expiring license via a one-time, upfront purchase. The new approach to licensing offers greater flexibility and ensures users can choose the option that best fits their needs. Genie 4.0 software will be available for download and licensing beginning mid-July. In the meantime, customers can explore the expanded features, service and support offering, flexible licensing options, and Genie 4.0 scripting resources.お知らせ • May 13Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: $7.65お知らせ • May 06Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. reaffirmed revenue guidance for the fiscal year ending December 31, 2023. For the year, the company expected reported revenue growth of 6% - 9% and organic revenue growth of 4% - 7%.Reported Earnings • May 03First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.098 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.098 loss in 1Q 2022). Revenue: US$182.1m (up 12% from 1Q 2022). Net loss: US$41.9m (loss widened 137% from 1Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Electronic industry in Germany.お知らせ • Feb 15Mirion Technologies, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. provided revenue guidance for the fiscal year ending December 31, 2023. For the period, The company expects revenue growth of 6% to 9%, organic growth of 4% to 7%.Reported Earnings • Feb 15Full year 2022 earnings releasedFull year 2022 results: US$1.38 loss per share. Revenue: US$717.8m (up 11% from FY 2021). Net loss: US$276.9m (loss widened 8.2% from FY 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Electronic industry in Germany.お知らせ • Feb 01Mirion Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023Mirion Technologies, Inc. announced that they will report Q4, 2022 results on Feb 14, 2023Breakeven Date Change • Nov 18No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$41.3m in 2023. New consensus forecast suggests the company will make a loss of US$19.8m in 2023.Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.26 loss per share (vs US$7.01 loss in 3Q 2021)Third quarter 2022 results: US$0.26 loss per share. Revenue: US$160.9m (up 12% from 3Q 2021). Net loss: US$47.1m (flat on 3Q 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.お知らせ • Nov 03Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Year 2022Mirion Technologies, Inc. reaffirmed revenue guidance for the year 2022. The company have reaffirmed organic revenue growth guidance of 4% to 6%.Board Change • Oct 31Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 25Mirion Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022Mirion Technologies, Inc. announced that they will report Q3, 2022 results After-Market on Nov 01, 2022お知らせ • Oct 04Mirion Technologies Appoints Michael Rossi as President of Mirion MedicalMirion Technologies, Inc. announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing levels of responsibility. Michael also brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International to the Mirion team. Michael earned a Bachelor of Science in Pharmacy degree from the University of the Sciences – Philadelphia College of Pharmacy and carries the Authorized Nuclear Pharmacist Certification from Butler University. Michael has also served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania.Buying Opportunity • Oct 01Now 20% undervaluedOver the last 90 days, the stock is up 33%. The fair value is estimated to be €9.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 75% in the next year.お知らせ • Sep 20Mirion Technologies, Inc. Announces Board ChangesOn September 13, 2022, Christopher Warren, a member of the board of directors (the “Board”) of Mirion Technologies, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022. On September 16, 2022, after recommendation by the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Sheila Rege, M.D., as a member of the Board, effective immediately, to fill the vacancy created by Mr. Warren’s resignation. Dr. Rege will stand for reelection as a member of the Board at the Company’s 2023 annual meeting of stockholders. Dr. Rege was also appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board. Dr. Rege is a board-certified radiation oncologist and the Chief Executive Officer and Founder of Northwest Cancer Clinic. Dr. Rege joins the Mirion team with over 30 years of experience in the field of nuclear medicine and radiation oncology. From 2007 to 2019 Dr. Rege served on the board of directors of Physicians Insurance, serving as the Chair of the Nominating Committee and a member of the Compensation, Executive and CEO Succession Committee. Dr. Rege is the recipient of numerous awards and accolades including the American Medical Association Women Physician Section Inspiration Award in 2021, the Private Company Boardroom 2022 “Directors to Watch,” The American College of Radiation Oncology 2022 Sucha Asbell Mentorship Award, and has been recognized as a “Top Oncologist” by Consumer Research Council of America in 2012. Dr. Rege received her B.A. from the University of California, Berkeley, and her M.D. from the University of California, Los Angeles.Buying Opportunity • Sep 03Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.4%. The fair value is estimated to be €9.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 96% in the next year.Breakeven Date Change • Sep 01Forecast breakeven date pushed back to 2023The 3 analysts covering Mirion Technologies previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 77% to 2022. The company is expected to make a profit of US$41.3m in 2023. Average annual earnings growth of 154% is required to achieve expected profit on schedule.お知らせ • Aug 10Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace.Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace on August 9, 2022. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of ARINC Incorporated from Collins Aerospace on August 9, 2022.Reported Earnings • Jul 30Second quarter 2022 earnings released: US$0.32 loss per share (vs US$8.14 loss in 2Q 2021)Second quarter 2022 results: US$0.32 loss per share. Revenue: US$175.8m (down 2.3% from 2Q 2021). Net loss: US$58.6m (loss widened 8.7% from 2Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the industry in Germany.お知らせ • Jul 16Mirion Technologies, Inc. to Report Q2, 2022 Results on Jul 29, 2022Mirion Technologies, Inc. announced that they will report Q2, 2022 results on Jul 29, 2022お知らせ • May 21Mirion Technologies, Inc. Appoints Christopher Moore as Principal Accounting OfficerOn May 18, 2022, Mirion Technologies, Inc. appointed Christopher Moore as Principal Accounting Officer, effective immediately. Mr. Moore joined the Corporation in April 2022 and, in his new role, will lead the global accounting organization and be responsible for advancing the Corporation's accounting and internal financial controls. Mr. Moore will report directly to the Corporation's CFO, Brian Schopfer.Reported Earnings • May 08First quarter 2022 earnings released: US$0.098 loss per share (vs US$6.18 loss in 1Q 2021)First quarter 2022 results: US$0.098 loss per share (up from US$6.18 loss in 1Q 2021). Revenue: US$163.2m (down 1.8% from 1Q 2021). Net loss: US$17.7m (loss narrowed 56% from 1Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 28% growth forecast for the industry in Germany.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Founder, CEO & Director Tom Logan was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 21+ 1 more updateMirion Technologies, Inc., Annual General Meeting, Jun 15, 2022Mirion Technologies, Inc., Annual General Meeting, Jun 15, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect directors for a one-year term; to ratify the appointment of Deloitte & Touche, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement; to approve, on an advisory basis, the frequency of future stockholder advisory votes on the compensation of the named executive officers; and to transact any other business as may properly come before the meeting or any adjournment or postponement thereof.お知らせ • Apr 12Mirion Technologies, Inc. Introduces New SaaS Option for its SunCHECK™ Quality Management PlatformMirion Technologies, Inc. announced the release of an enhanced Cloud-hosted, SaaS option for its SunCHECK™ Quality Management Platform. Through a centralized database and single interface, the SunCHECK Platform streamlines and standardizes workflows for Radiation Therapy Quality Assurance (QA) – to reduce risk and improve Patient Safety in cancer care. The SaaS model offers scalability, security, and operational efficiencies for health systems looking to integrate and automate QA, with a comprehensive, proven solution. Local management of software and servers can be burdensome, requiring capital for server hardware. Cloud-hosted, SaaS implementation of the SunCHECK Platform reduces the time and resources required for upfront deployment and ongoing support. SunCHECK users and their IT departments can be assured of reliability, redundancy, and security, with Amazon Web Services as the Cloud provider for the SunCHECK SaaS option. The SunCHECK SaaS solution can be customized to meet any clinic’s radiation oncology quality management needs and is accessed through a secure Internet connection. At this time, the SunCHECK SaaS Solution is available for new SunCHECK Platform customers in approved markets only. The SunCHECK software will be featured, and available for demonstration, in the Sun Nuclear booth during ESTRO 2022, May 6-10, in Copenhagen, Denmark. ESTRO 2022 is the annual meeting of the European Society for Radiotherapy and Oncology, with a membership base of 7,600 Radiation Oncology professionals globally.お知らせ • Mar 10Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million.Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million on December 1, 2021. The total consideration of $1.5 million includes $0.5 million contingent consideration, based on actual revenues from existing customers for 6 months subsequent to the transaction date. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Safeline Monitors Systems LLC on December 1, 2021.Reported Earnings • Mar 06Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$644.2m (up 13% from FY 2020). Net loss: US$255.8m (loss widened 65% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 23% growth forecast for the industry in Germany.お知らせ • Mar 06Mirion Technologies, Inc. Announces Executive ChangesOn February 28, 2022, Ms. Kipling Matas, who has served as the Principal Accounting Officer of Mirion Technologies, Inc. resigned from her position, effective March 23, 2022. Mr. Brian Schopfer, Chief Financial Officer, will assume the role of Principal Accounting Officer, effective upon her departure. Ms. Matas has agreed to continue assisting the Company with the transition through May 2022 under a consulting arrangement.お知らせ • Feb 24Mirion Technologies, Inc. Announces Executive ChangesOn February 18, 2022, Mirion Technologies, Inc. determined that Michael Freed, who has served as the Chief Operating Officer of the Company, will depart the Company on February 28, 2022 as a result of his position being eliminated. In connection with his departure, Mr. Freed will be eligible for separation payments and benefits as provided in his employment agreement with the Company.お知らせ • Feb 10Mirion Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022Mirion Technologies, Inc. announced that they will report Q4, 2021 results on Feb 23, 2022お知らせ • Dec 16Mirion Technologies, Inc. Launches the Hyperion™ Compact Digital Radiation Tolerant CameraMirion Technologies, Inc. announced the release of the Hyperion™ Compact Digital High Radiation Tolerant Camera, now offered in color and monochrome versions. With the Hyperion Compact camera’s digital performance and radiation tolerance, cost of ownership can be reduced while performance is enhanced—all within a compact package. The Mirion Hyperion™ Compact camera builds on years of research and development into digital radiation tolerant electronics combined with Mirion’s unique color processing algorithms, to provide an unsurpassed user experience for high radiation tolerant imaging with no heavy radiation shielding required.Reported Earnings • Nov 14First quarter 2022 earnings released: US$7.01 loss per share (vs US$3.58 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$144.3m (up 2.2% from 1Q 2021). Net loss: US$46.7m (loss widened 91% from 1Q 2021).業績と収益の成長予測DB:55I0 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,322124227192412/31/20271,22586201222812/31/20261,1405116120883/31/20269812589127N/A12/31/202592529107143N/A9/30/20259022793131N/A6/30/20258861084126N/A3/31/2025870-1084129N/A12/31/2024861-365099N/A9/30/2024837-6656105N/A6/30/2024821-6567112N/A3/31/2024811-8162104N/A12/31/2023801-975895N/A9/30/2023788-2351753N/A6/30/2023758-270-1916N/A3/31/2023737-301-825N/A12/31/2022718-277539N/A9/30/2022678-205-274N/A6/30/2022661-204-429N/A3/31/2022665-199335N/A12/31/2021668-222335N/A9/30/2021641-1654471N/A6/30/2021612-1583054N/A3/31/2021573-1552853N/A6/30/2020478-1192040N/A6/30/2019440-122N/A15N/A6/30/2018444-104N/A16N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 55I0の予測収益成長率 (年間49.5% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: 55I0の収益 ( 49.5% ) はGerman市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: 55I0の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 55I0の収益 ( 10.4% ) German市場 ( 6.4% ) よりも速いペースで成長すると予測されています。高い収益成長: 55I0の収益 ( 10.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 55I0の 自己資本利益率 は、3年後には低くなると予測されています ( 9.6 %)。成長企業の発掘7D1Y7D1Y7D1YTech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/06 13:42終値2026/05/06 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mirion Technologies, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Quinn FredricksonBairdRobert MasonBairdYuan ZhiB. Riley Securities, Inc.9 その他のアナリストを表示
お知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.
お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.
お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.
お知らせ • Apr 30Mirion Technologies, Inc. Revises Earnings Guidance for the Full Year 2025Mirion Technologies, Inc. revised earnings guidance for the full year 2025. Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08. Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024.
お知らせ • Feb 13Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points. Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024.
お知らせ • Dec 04Mirion Technologies, Inc. Provides Earnings Guidance for the Year 2025Mirion Technologies, Inc. provided earnings guidance for the year 2025. For the year, the company expects Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024. Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points.
お知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.
お知らせ • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026
お知らせ • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.
お知らせ • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.
お知らせ • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026
お知らせ • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.
お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.
お知らせ • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025
お知らせ • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35
お知らせ • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6
お知らせ • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.
お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.
お知らせ • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.
お知らせ • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
お知らせ • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value Index
お知らせ • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.
お知らせ • Apr 30Mirion Technologies, Inc. Revises Earnings Guidance for the Full Year 2025Mirion Technologies, Inc. revised earnings guidance for the full year 2025. Revenue growth of approximately 5.0% – 7.0% (previously 4.0% – 6.0%); includes a foreign exchange rate headwind of approximately 40 basis points using a Euro-to-USD exchange rate of 1.08. Organic Revenue growth of approximately 5.5% – 7.5% (no change from previous guidance); includes an approximately 30 basis point lasers business closure headwind from 2024.
お知らせ • Apr 21Mirion Technologies, Inc. to Report Q1, 2025 Results on Apr 29, 2025Mirion Technologies, Inc. announced that they will report Q1, 2025 results After-Market on Apr 29, 2025
お知らせ • Apr 03Mirion Technologies, Inc., Annual General Meeting, May 15, 2025Mirion Technologies, Inc., Annual General Meeting, May 15, 2025.
お知らせ • Apr 02Mirion Technologies, Inc. to Elevate Radiopharmaceutical Production Quality with Advanced Apex-Guard SoftwareMirion Technologies announced the latest release of its Apex-Guard gamma spectroscopy software. Tailored to meet the stringent regulatory demands of commercial radioisotope producers, Apex-Guard software V1.2 significantly enhances the Mirion solutions suite within the radiopharmaceutical supply chain with a robust impurity analysis for radioisotope producers. This software release reinforces the Mirion commitment to improving quality in cancer care, through focused innovation across its Mirion Technologies and Mirion Medical groups. The radiopharmaceutical field is experiencing rapid expansion, with over 100 drugs currently in Phase I or further clinical development stages poised to revolutionize patient-centric diagnosis and treatment in cancer care and other medical specialties. To manage the growth, radioisotope producers require robust quality management and impurity analysis to ensure compliance and patient safety. Building on the established Mirion Technologies Genie and Apex-Gamma gamma spectroscopy software platforms, Apex-Guard software offers advanced controls, security, audit features, and data integrity. These features support compliance with regulations such as U.S. FDA 21 CFR Part 112. The latest version introduces a solution for Radionuclidic purity gamma spectroscopy measurements through a broadly applicable, ready-to-use patent-pending algorithm. This advancement streamlines quality management processes, increases confidence in quality and facilitates efficient regulatory compliance. Apex-Guard software further enhances the radiopharmaceutical lifecycle through streamlined workflows via interoperability with industry-leader BioTrax QMS, an electronic quality management tool encompassing inventory management, document management, and production batch records from ec2 Software, a Mirion Medical Company.
お知らせ • Mar 01Mirion Technologies Site in Munich Achieves ISO 19443 CertificationMirion Technologies announced that its site in Munich, Germany, has been awarded with the International Organization for Standardization (ISO) certification ISO 19343:2018, a nuclear-specific quality management standard dedicated to organizations supplying products and services important to nuclear safety (ITNS). Such achievement emphasizes the company's commitment to maintaining stringent quality and safety standards specific to the nuclear sector. The Mirion Technologies site in Munich, a full-service provider for Radiation and Neutron Flux Monitoring Systems, is one of a few companies in Germany to receive this certification, building on its long-standing ISO 9001 certification and further enhancing the Mirion commitment to excellence. The audit was conducted by TUV Sud France, accredited by the French Accreditation Body COFRAC. The certification audit specifically highlighted the company's clear line of responsibility, quality concept and emphasis on nuclear quality goals. The auditors also praised the interaction between departments and the well-structured approach to projects and developments. The Munich site joins three other Mirion locations to achieve the ISO 19343 certification. Mirion Technologies sites in France (Lamanon and Fussy) are also accredited.
お知らせ • Feb 13Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 4.0% – 6.0%; includes a foreign exchange rate headwind of approximately 190 basis points. Organic Revenue growth of approximately 5.5% – 7.5%; includes an approximately 30 basis point lasers business closure headwind from 2024.
お知らせ • Jan 17Mirion Technologies, Inc. to Report Q4, 2024 Results on Feb 11, 2025Mirion Technologies, Inc. announced that they will report Q4, 2024 results After-Market on Feb 11, 2025
お知らせ • Dec 04Mirion Technologies, Inc. Provides Earnings Guidance for the Year 2025Mirion Technologies, Inc. provided earnings guidance for the year 2025. For the year, the company expects Organic revenue growth of approximately 5.5% - 7.5%; includes an approximately 30 basis point lasers business divestiture headwind from 2024. Revenue growth of approximately 4.0% - 6.0%; includes a foreign exchange rate headwind of approximately 150 basis points.
お知らせ • Dec 03Mirion Technologies, Inc. (NYSE:MIR) announces an Equity Buyback for $100 million worth of its shares.Mirion Technologies, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its Class A common stock.
Reported Earnings • Oct 30Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.061 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (further deteriorated from US$0.061 loss in 3Q 2023). Revenue: US$206.8m (up 8.2% from 3Q 2023). Net loss: US$13.6m (loss widened 12% from 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 30Mirion Technologies, Inc. Revises Financial Guidance for the Fiscal Year Ending December 31, 2024Mirion Technologies, Inc. revised financial guidance for the fiscal year ending December 31, 2024. For the period, the company expects revenue growth of 6% to 7%, compared to 5% to 7% previously and Organic revenue growth of 5% to 6%, compared to 4% to 6% previously.
New Risk • Oct 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$31m net loss next year). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€250k sold).
お知らせ • Oct 17Mirion Technologies, Inc. to Report Q3, 2024 Results on Oct 29, 2024Mirion Technologies, Inc. announced that they will report Q3, 2024 results After-Market on Oct 29, 2024
New Risk • Aug 09New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €328k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$27m net loss next year). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Significant insider selling over the past 3 months (€328k sold).
お知らせ • Aug 03Mirion Technologies, Inc. Reiterates Revenue Guidance for the Full Year Period Ending December 31, 2024Mirion Technologies, Inc. reiterated revenue guidance for the full year period ending December 31, 2024. For the year, the company expects revenue growth guidance of 5% to 7%. Organic revenue growth of 4% - 6%, which is unchanged.
Reported Earnings • Aug 02Second quarter 2024 earnings released: US$0.058 loss per share (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: US$0.058 loss per share (improved from US$0.14 loss in 2Q 2023). Revenue: US$207.1m (up 5.0% from 2Q 2023). Net loss: US$11.7m (loss narrowed 58% from 2Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Share price has been volatile over the past 3 months (6.6% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).
お知らせ • Jul 20Mirion Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024Mirion Technologies, Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024
New Risk • Jul 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).
New Risk • Jun 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding).
New Risk • May 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$32m net loss next year). Shareholders have been diluted in the past year (2.7% increase in shares outstanding).
Breakeven Date Change • May 02No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.8m in 2025.
Reported Earnings • May 01First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (improved from US$0.22 loss in 1Q 2023). Revenue: US$192.6m (up 5.8% from 1Q 2023). Net loss: US$25.8m (loss narrowed 38% from 1Q 2023). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.
お知らせ • May 01Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024Mirion Technologies, Inc. reaffirmed earnings Guidance for the year ending December 31, 2024. The company expected revenue growth of 5% - 7%. Organic revenue growth of 4% - 6%.
Board Change • Apr 25High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 24Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024Mirion Technologies, Inc., Annual General Meeting, Jun 04, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider Elect directors for a one-year term; to Ratify the appointment of Deloitte & Touche, LLP (“Deloitte”) as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to Approve, on a non-binding advisory basis, the compensation of company's named executive officers as disclosed in the accompanying proxy statement (the “Say-on-Pay Proposal”); and to transact any other business as may properly come before the meeting or any adjournment, postponement or continuation thereof.
New Risk • Apr 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$13m net loss in 2 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding).
お知らせ • Apr 19Mirion Technologies, Inc. to Report Q1, 2024 Results on Apr 30, 2024Mirion Technologies, Inc. announced that they will report Q1, 2024 results After-Market on Apr 30, 2024
Reported Earnings • Mar 04Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022)Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Electronic industry in Germany.
Breakeven Date Change • Feb 15No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$91.3m in 2025. New consensus forecast suggests the company will make a loss of US$12.5m in 2025.
Reported Earnings • Feb 14Full year 2023 earnings released: US$0.49 loss per share (vs US$1.53 loss in FY 2022)Full year 2023 results: US$0.49 loss per share (improved from US$1.53 loss in FY 2022). Revenue: US$800.9m (up 12% from FY 2022). Net loss: US$96.9m (loss narrowed 65% from FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Electronic industry in Germany.
お知らせ • Feb 14Mirion Technologies, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2024Mirion Technologies, Inc. provided earnings guidance for the fiscal year ending December 31, 2024. For the year, the company expects revenue growth of 5% - 7%, and Organic revenue growth of 4% - 6%.
お知らせ • Feb 01Mirion Technologies, Inc. to Report Q4, 2023 Results on Feb 13, 2024Mirion Technologies, Inc. announced that they will report Q4, 2023 results After-Market on Feb 13, 2024
お知らせ • Nov 03Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million.Mirion Technologies, Inc. (NYSE:MIR) acquired Nuclear Medicine Information Systems, LLC for $33 million on November 1, 2023. The ec 2 team and portfolio of solutions will be integrated into Mirion’s Nuclear Medicine business unit.Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Nuclear Medicine Information Systems, LLC on November 1, 2023.
Reported Earnings • Nov 02Third quarter 2023 earnings released: US$0.061 loss per share (vs US$0.26 loss in 3Q 2022)Third quarter 2023 results: US$0.061 loss per share (improved from US$0.26 loss in 3Q 2022). Revenue: US$191.2m (up 19% from 3Q 2022). Net loss: US$12.1m (loss narrowed 74% from 3Q 2022). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.
お知らせ • Nov 02Mirion Technologies, Inc. Reiterates Revenue Guidance for the Twelve Month Period Ending December 31, 2023Mirion Technologies, Inc. reiterates revenue guidance for the twelve month period ending December 31, 2023. The company expects Revenue growth of 8% - 10% and Organic revenue growth of 6% - 8%.
お知らせ • Oct 19Mirion Announces Resignation of Michael Rossi as Medical Group President, Effective November 1, 2023Mirion announced that Michael Rossi has informed the Company of his decision to resign as Medical Group President, effective November 1, 2023, in order to assume a CEO role at another public company. Mirion’s Chief Executive Officer, Thomas Logan, will reassume the responsibilities of Medical Group President until a permanent successor is named. Mr. Logan had previously served as acting Medical Group President through much of 2022.
お知らせ • Oct 18Mirion Technologies, Inc. to Report Q3, 2023 Results on Nov 01, 2023Mirion Technologies, Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023
New Risk • Aug 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$270m Forecast net loss in 1 year: US$59m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$59m net loss next year). Shareholders have been diluted in the past year (9.3% increase in shares outstanding).
Breakeven Date Change • Aug 03No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$60.9m in 2023. New consensus forecast suggests the company will make a loss of US$32.3m in 2024.
お知らせ • Aug 03Mirion Technologies, Inc. Updates Its Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. updated its revenue guidance for the fiscal year ending December 31, 2023. For the period, the company expects revenue growth of8% - 10%, compared to 6% - 9% previously and Organic revenue growth of 6% - 8%, compared to 4% - 7% previously.
New Risk • Jul 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
お知らせ • Jul 23Mirion Technologies, Inc. to Report Q2, 2023 Results on Aug 02, 2023Mirion Technologies, Inc. announced that they will report Q2, 2023 results on Aug 02, 2023
お知らせ • Jun 28Mirion Technologies Introduces Genie™? 4.0 Spectroscopy Software, Now with Flexible Licensing OptionsMirion Technologies announced a major update of the company's Genie spectroscopy software. With the release of Genie 4.0 software, Mirion builds upon nearly 40 years of leadership in spectroscopy solutions and services, delivering a range of new features that enhance efficiency and accuracy for both existing and new users, while introducing simplified software models and flexible purchasing options. Smart Design for All Longtime Genie software users will appreciate the seamless transition to Genie 4.0, as the update retains vital workflows and addresses key user requests, allowing them to maintain productivity and strengthen their expertise. Simultaneously, new users can quickly adapt to and harness the power of the Genie 4.0 release, ensuring evolved spectroscopy operations from the outset. Highlights of Genie 4.0 software include: User Experience Enhancements: Genie 4.0 features new Interactive Reports, enabling easier data visualization and detailed analysis, as well as customization per user requirements. Increased Accuracy and Reliable Results: New algorithms within Genie 4.0 improve uncertainty calculations for relationships in calibration standards and address a frequent user request for a new FWHM calibration curve, to further enhance accuracy. Improved Automation: New Python programming language-based scripting options enable custom and automated modulation of parameters, as well as extraction of specific parameters for analysis in a secondary system. Genie 4.0 software with Python compatibility also empowers users to perform custom calculations and update the analysis as needed, providing added flexibility and adaptability. Interested customers across the fields of Nuclear Power, Emergency Response, Environmental Labs, National Labs, Research, and Education are encouraged to view a free, introductory webinar, Latest in Gamma Spectroscopy: NewGenie 4.0 Software, on mirion.com. Continuous Support and Updates: In addition to a host of new features, the release of Genie 4.0 software introduces flexible new licensing models. Users now have the option to subscribe to the software over one-year or three-year terms with Priority Technical Support and software updates included, thereby lowering total cost of ownership and supporting Operational Expense (OpEx) budgeting. Users may also choose a non-expiring license via a one-time, upfront purchase. The new approach to licensing offers greater flexibility and ensures users can choose the option that best fits their needs. Genie 4.0 software will be available for download and licensing beginning mid-July. In the meantime, customers can explore the expanded features, service and support offering, flexible licensing options, and Genie 4.0 scripting resources.
お知らせ • May 13Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $53.55 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: $7.65
お知らせ • May 06Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. reaffirmed revenue guidance for the fiscal year ending December 31, 2023. For the year, the company expected reported revenue growth of 6% - 9% and organic revenue growth of 4% - 7%.
Reported Earnings • May 03First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.098 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.098 loss in 1Q 2022). Revenue: US$182.1m (up 12% from 1Q 2022). Net loss: US$41.9m (loss widened 137% from 1Q 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Electronic industry in Germany.
お知らせ • Feb 15Mirion Technologies, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2023Mirion Technologies, Inc. provided revenue guidance for the fiscal year ending December 31, 2023. For the period, The company expects revenue growth of 6% to 9%, organic growth of 4% to 7%.
Reported Earnings • Feb 15Full year 2022 earnings releasedFull year 2022 results: US$1.38 loss per share. Revenue: US$717.8m (up 11% from FY 2021). Net loss: US$276.9m (loss widened 8.2% from FY 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Electronic industry in Germany.
お知らせ • Feb 01Mirion Technologies, Inc. to Report Q4, 2022 Results on Feb 14, 2023Mirion Technologies, Inc. announced that they will report Q4, 2022 results on Feb 14, 2023
Breakeven Date Change • Nov 18No longer forecast to breakevenThe 3 analysts covering Mirion Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$41.3m in 2023. New consensus forecast suggests the company will make a loss of US$19.8m in 2023.
Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.26 loss per share (vs US$7.01 loss in 3Q 2021)Third quarter 2022 results: US$0.26 loss per share. Revenue: US$160.9m (up 12% from 3Q 2021). Net loss: US$47.1m (flat on 3Q 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany.
お知らせ • Nov 03Mirion Technologies, Inc. Reaffirms Revenue Guidance for the Year 2022Mirion Technologies, Inc. reaffirmed revenue guidance for the year 2022. The company have reaffirmed organic revenue growth guidance of 4% to 6%.
Board Change • Oct 31Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 25Mirion Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022Mirion Technologies, Inc. announced that they will report Q3, 2022 results After-Market on Nov 01, 2022
お知らせ • Oct 04Mirion Technologies Appoints Michael Rossi as President of Mirion MedicalMirion Technologies, Inc. announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing levels of responsibility. Michael also brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International to the Mirion team. Michael earned a Bachelor of Science in Pharmacy degree from the University of the Sciences – Philadelphia College of Pharmacy and carries the Authorized Nuclear Pharmacist Certification from Butler University. Michael has also served on several Boards of Directors and remains a Licensed Pharmacist in the state of Pennsylvania.
Buying Opportunity • Oct 01Now 20% undervaluedOver the last 90 days, the stock is up 33%. The fair value is estimated to be €9.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 75% in the next year.
お知らせ • Sep 20Mirion Technologies, Inc. Announces Board ChangesOn September 13, 2022, Christopher Warren, a member of the board of directors (the “Board”) of Mirion Technologies, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective at the close of business on September 16, 2022. On September 16, 2022, after recommendation by the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Sheila Rege, M.D., as a member of the Board, effective immediately, to fill the vacancy created by Mr. Warren’s resignation. Dr. Rege will stand for reelection as a member of the Board at the Company’s 2023 annual meeting of stockholders. Dr. Rege was also appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board. Dr. Rege is a board-certified radiation oncologist and the Chief Executive Officer and Founder of Northwest Cancer Clinic. Dr. Rege joins the Mirion team with over 30 years of experience in the field of nuclear medicine and radiation oncology. From 2007 to 2019 Dr. Rege served on the board of directors of Physicians Insurance, serving as the Chair of the Nominating Committee and a member of the Compensation, Executive and CEO Succession Committee. Dr. Rege is the recipient of numerous awards and accolades including the American Medical Association Women Physician Section Inspiration Award in 2021, the Private Company Boardroom 2022 “Directors to Watch,” The American College of Radiation Oncology 2022 Sucha Asbell Mentorship Award, and has been recognized as a “Top Oncologist” by Consumer Research Council of America in 2012. Dr. Rege received her B.A. from the University of California, Berkeley, and her M.D. from the University of California, Los Angeles.
Buying Opportunity • Sep 03Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.4%. The fair value is estimated to be €9.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 13% in a year. Earnings is forecast to grow by 96% in the next year.
Breakeven Date Change • Sep 01Forecast breakeven date pushed back to 2023The 3 analysts covering Mirion Technologies previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 77% to 2022. The company is expected to make a profit of US$41.3m in 2023. Average annual earnings growth of 154% is required to achieve expected profit on schedule.
お知らせ • Aug 10Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace.Mirion Technologies, Inc. (NYSE:MIR) acquired ARINC Incorporated from Collins Aerospace on August 9, 2022. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of ARINC Incorporated from Collins Aerospace on August 9, 2022.
Reported Earnings • Jul 30Second quarter 2022 earnings released: US$0.32 loss per share (vs US$8.14 loss in 2Q 2021)Second quarter 2022 results: US$0.32 loss per share. Revenue: US$175.8m (down 2.3% from 2Q 2021). Net loss: US$58.6m (loss widened 8.7% from 2Q 2021). Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the industry in Germany.
お知らせ • Jul 16Mirion Technologies, Inc. to Report Q2, 2022 Results on Jul 29, 2022Mirion Technologies, Inc. announced that they will report Q2, 2022 results on Jul 29, 2022
お知らせ • May 21Mirion Technologies, Inc. Appoints Christopher Moore as Principal Accounting OfficerOn May 18, 2022, Mirion Technologies, Inc. appointed Christopher Moore as Principal Accounting Officer, effective immediately. Mr. Moore joined the Corporation in April 2022 and, in his new role, will lead the global accounting organization and be responsible for advancing the Corporation's accounting and internal financial controls. Mr. Moore will report directly to the Corporation's CFO, Brian Schopfer.
Reported Earnings • May 08First quarter 2022 earnings released: US$0.098 loss per share (vs US$6.18 loss in 1Q 2021)First quarter 2022 results: US$0.098 loss per share (up from US$6.18 loss in 1Q 2021). Revenue: US$163.2m (down 1.8% from 1Q 2021). Net loss: US$17.7m (loss narrowed 56% from 1Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 28% growth forecast for the industry in Germany.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Founder, CEO & Director Tom Logan was the last director to join the board, commencing their role in 2005. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 21+ 1 more updateMirion Technologies, Inc., Annual General Meeting, Jun 15, 2022Mirion Technologies, Inc., Annual General Meeting, Jun 15, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect directors for a one-year term; to ratify the appointment of Deloitte & Touche, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the named executive officers as disclosed in the proxy statement; to approve, on an advisory basis, the frequency of future stockholder advisory votes on the compensation of the named executive officers; and to transact any other business as may properly come before the meeting or any adjournment or postponement thereof.
お知らせ • Apr 12Mirion Technologies, Inc. Introduces New SaaS Option for its SunCHECK™ Quality Management PlatformMirion Technologies, Inc. announced the release of an enhanced Cloud-hosted, SaaS option for its SunCHECK™ Quality Management Platform. Through a centralized database and single interface, the SunCHECK Platform streamlines and standardizes workflows for Radiation Therapy Quality Assurance (QA) – to reduce risk and improve Patient Safety in cancer care. The SaaS model offers scalability, security, and operational efficiencies for health systems looking to integrate and automate QA, with a comprehensive, proven solution. Local management of software and servers can be burdensome, requiring capital for server hardware. Cloud-hosted, SaaS implementation of the SunCHECK Platform reduces the time and resources required for upfront deployment and ongoing support. SunCHECK users and their IT departments can be assured of reliability, redundancy, and security, with Amazon Web Services as the Cloud provider for the SunCHECK SaaS option. The SunCHECK SaaS solution can be customized to meet any clinic’s radiation oncology quality management needs and is accessed through a secure Internet connection. At this time, the SunCHECK SaaS Solution is available for new SunCHECK Platform customers in approved markets only. The SunCHECK software will be featured, and available for demonstration, in the Sun Nuclear booth during ESTRO 2022, May 6-10, in Copenhagen, Denmark. ESTRO 2022 is the annual meeting of the European Society for Radiotherapy and Oncology, with a membership base of 7,600 Radiation Oncology professionals globally.
お知らせ • Mar 10Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million.Mirion Technologies, Inc. (NYSE:MIR) acquired Safeline Monitors Systems LLC for $1.5 million on December 1, 2021. The total consideration of $1.5 million includes $0.5 million contingent consideration, based on actual revenues from existing customers for 6 months subsequent to the transaction date. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Safeline Monitors Systems LLC on December 1, 2021.
Reported Earnings • Mar 06Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$644.2m (up 13% from FY 2020). Net loss: US$255.8m (loss widened 65% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 23% growth forecast for the industry in Germany.
お知らせ • Mar 06Mirion Technologies, Inc. Announces Executive ChangesOn February 28, 2022, Ms. Kipling Matas, who has served as the Principal Accounting Officer of Mirion Technologies, Inc. resigned from her position, effective March 23, 2022. Mr. Brian Schopfer, Chief Financial Officer, will assume the role of Principal Accounting Officer, effective upon her departure. Ms. Matas has agreed to continue assisting the Company with the transition through May 2022 under a consulting arrangement.
お知らせ • Feb 24Mirion Technologies, Inc. Announces Executive ChangesOn February 18, 2022, Mirion Technologies, Inc. determined that Michael Freed, who has served as the Chief Operating Officer of the Company, will depart the Company on February 28, 2022 as a result of his position being eliminated. In connection with his departure, Mr. Freed will be eligible for separation payments and benefits as provided in his employment agreement with the Company.
お知らせ • Feb 10Mirion Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022Mirion Technologies, Inc. announced that they will report Q4, 2021 results on Feb 23, 2022
お知らせ • Dec 16Mirion Technologies, Inc. Launches the Hyperion™ Compact Digital Radiation Tolerant CameraMirion Technologies, Inc. announced the release of the Hyperion™ Compact Digital High Radiation Tolerant Camera, now offered in color and monochrome versions. With the Hyperion Compact camera’s digital performance and radiation tolerance, cost of ownership can be reduced while performance is enhanced—all within a compact package. The Mirion Hyperion™ Compact camera builds on years of research and development into digital radiation tolerant electronics combined with Mirion’s unique color processing algorithms, to provide an unsurpassed user experience for high radiation tolerant imaging with no heavy radiation shielding required.
Reported Earnings • Nov 14First quarter 2022 earnings released: US$7.01 loss per share (vs US$3.58 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: US$144.3m (up 2.2% from 1Q 2021). Net loss: US$46.7m (loss widened 91% from 1Q 2021).